Existing Partners
Below you will find a list of our existing partners.
In January 2012 Evolva announced the signing of an agreement with Roquette Frères SA for joint research and development of novel and optimised biosynthetic production routes for an ingredient with important applications in food products. Roquette is a world leader in the area of nutrition and other products based on raw vegetable materials.
Evolva is a member of a group of European companies and academic institutions (DIABAT), researching the role of brown adipose tissue (BAT) in the prevention and treatment of obesity and type 2 diabetes. Type 2 diabetes and its associated cardio-vascular complications have emerged as the leading causes of death in Western countries, associated with estimated health care costs of more than 30 billion Euros in the European Union per year. The DIABAT project will run for 4 years and is part-funded by the European Commission within the FP-7 programme.
In March 2011, Evolva signed an agreement with BASF for joint research on the design of novel and optimised biosynthesis routes for selected natural products with crop protection potential. This is Evolva’s first collaboration in which its technology is applied to the agricultural sector. BASF is the world’s leading chemical company with sales of EUR 63.9 billion in 2010.
In January 2011 Evolva announced a collaboration and joint development agreement with International Flavors & Fragrances Inc. (IFF), one of the world’s leading creators and manufacturers of flavours and fragrances for consumer products. The objective of the collaboration is to implement a commercially viable biosynthetic route for the production of a key flavouring ingredient.
In January 2010, Evolva signed an agreement with Roche to create compounds with activity on targets in oncology and anti-infectives using Evolva’s biosynthetic approach.
Evolva aims to find approaches for a commercially viable and environmentally acceptable production of vanillin as part of the application of its synthetic biology platform to “white” biotechnology (the application of biotechnology for industrial purposes).
In DIVINOCELL (an EC-funded FP7 initiative) Evolva is part of a consortium of companies and academic laboratories. The goal of the program is to find compounds that curb the proliferation and viability of Gram-negative bacterial pathogens by inhibiting their machinery for cell division. Further information on this program can be found at http://www.cnb.csic.es/~divinocell/.
Evolva, Inc., Evolva’s American subsidiary has been mandated by the US Army Research Office (ARO) to discover compounds that inhibit the growth of the gram negative bacterial pathogen Burkholderia pseudomallei. The targets in this program have potential utility for other gram negative bacteria.
What we offer
Nutrition & Consumer
Pharmaceuticals
Technology
